HALLE/SAALE, Germany, Jan. 4 2012 - Probiodrug AG today announced it has secured EUR15 million additional financing for the ongoing development of its glutaminyl cyclase (QC) inhibitor program. The …
ProBiodrug – Neurodegeneration bei Alzheimer-Erkrankung: Schlüsselrolle von QC
Probiodrug veröffentlicht neue Erkenntnisse zur Entstehung von Alzheimer im Journal of Neuroscience Halle/Saale, 8. September 2011 -- Die Probiodrug AG, ein biopharmazeutisches Unternehmen, das sich …
Probiodrug discovered fundamentally new active principle for the treatment of inflammatory diseases
Publikation in EMBO Molecular Medicine erläutert kausale Rolle des Enzyms iso-Glutaminylzyklase (isoQC) Halle/Saale, 20. Juli 2011, 08:00 Uhr MESZ -- Die Probiodrug AG, ein biopharmazeutisches …
Probiodrug and its collaborators will present novel insights into the pathophysiology of AD and biomarkers at AD/PD 2011 in Barcelona
Halle/Saale, March 08th 2011 -- Probiodrug AG (Probiodrug), a biotech company developing novel concepts and products for the treatment of neurodegenerative and inflammatory diseases with a particular …